CO2023013397A2 - Compuestos de tienopirrol - Google Patents

Compuestos de tienopirrol

Info

Publication number
CO2023013397A2
CO2023013397A2 CONC2023/0013397A CO2023013397A CO2023013397A2 CO 2023013397 A2 CO2023013397 A2 CO 2023013397A2 CO 2023013397 A CO2023013397 A CO 2023013397A CO 2023013397 A2 CO2023013397 A2 CO 2023013397A2
Authority
CO
Colombia
Prior art keywords
compounds
present description
lupus erythematosus
pharmaceutical compositions
thienopyrrole compounds
Prior art date
Application number
CONC2023/0013397A
Other languages
English (en)
Inventor
Scott E Lazerwith
Yasamin Moazami
Scott D Schroeder
Eda Y Canales
Daniel G Shore
Stephen E Ammann
Weng K Chang
Michael L Mitchell
Henok H Kinfe
Christopher J Swank
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CO2023013397A2 publication Critical patent/CO2023013397A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se relaciona generalmente con ciertos compuestos, composiciones farmacéuticas que comprenden dichos compuestos y métodos para preparar y usar dichos compuestos y composiciones farmacéuticas. Los compuestos y composiciones proporcionados en la presente descripción pueden usarse para el tratamiento o prevención de una enfermedad autoinmunitaria y/o condición inflamatoria, que incluye el lupus eritematoso sistémico y lupus eritematoso cutáneo.
CONC2023/0013397A 2021-04-16 2023-10-09 Compuestos de tienopirrol CO2023013397A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163176109P 2021-04-16 2021-04-16
US202163216418P 2021-06-29 2021-06-29
US202263305610P 2022-02-01 2022-02-01
PCT/US2022/024984 WO2022221642A1 (en) 2021-04-16 2022-04-15 Thienopyrrole compounds

Publications (1)

Publication Number Publication Date
CO2023013397A2 true CO2023013397A2 (es) 2023-10-30

Family

ID=81580723

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0013397A CO2023013397A2 (es) 2021-04-16 2023-10-09 Compuestos de tienopirrol

Country Status (13)

Country Link
US (2) US11661431B2 (es)
EP (1) EP4323369A1 (es)
JP (1) JP2024513945A (es)
KR (1) KR20230171469A (es)
AU (1) AU2022257039A1 (es)
BR (1) BR112023021107A2 (es)
CA (1) CA3214808A1 (es)
CO (1) CO2023013397A2 (es)
CR (1) CR20230478A (es)
DO (1) DOP2023000219A (es)
IL (1) IL307203A (es)
TW (1) TW202302598A (es)
WO (1) WO2022221642A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327574A (zh) * 2021-09-10 2023-07-16 美商基利科學股份有限公司 噻吩并吡咯化合物
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
US6329412B1 (en) 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
US8691859B2 (en) 2005-08-12 2014-04-08 The United States Of America As Represented By The Secretary Of The Army Broad spectrum antibacterial compounds
BRPI0616994A2 (pt) 2005-08-15 2011-07-05 Irm Llc compostos e composições como miméticos de tpo
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
BRPI0714346A2 (pt) * 2006-07-14 2013-03-19 Genelabs Tech Inc agentes antivirais
CN101583598B (zh) 2007-01-15 2012-09-12 参天制药株式会社 具有IκB激酶β抑制活性的新型吲哚衍生物
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
EP2350032B1 (en) 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazole compounds and methods of use
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
JP6093759B2 (ja) 2011-06-01 2017-03-08 ジャナス バイオセラピューティクス，インク． 新規の免疫系調節剤
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR101452579B1 (ko) 2012-08-17 2014-10-21 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2016156816A1 (en) 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
US20180312493A1 (en) 2015-11-04 2018-11-01 Simon Fraser University Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor
KR20180094939A (ko) 2015-12-17 2018-08-24 메르크 파텐트 게엠베하 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도
SG10201911665UA (en) 2016-04-15 2020-01-30 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
WO2017188287A1 (ja) 2016-04-26 2017-11-02 大日本住友製薬株式会社 置換プリン誘導体
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
US11180474B2 (en) 2016-07-30 2021-11-23 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
SG11201900947RA (en) 2016-08-08 2019-02-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
EP4059934A1 (en) 2016-09-09 2022-09-21 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
CN110944990A (zh) 2017-07-18 2020-03-31 默克专利股份公司 Tlr7/8拮抗剂及其用途
JP7104775B2 (ja) 2017-08-04 2022-07-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物
KR20200036913A (ko) 2017-08-04 2020-04-07 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
JP2021035910A (ja) 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
WO2019092739A1 (en) 2017-11-08 2019-05-16 Council Of Scientific & Industrial Research Purine based compounds as toll-like receptor 9 antagonist
KR20200086709A (ko) 2017-11-14 2020-07-17 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
SG11202005513TA (en) 2017-12-15 2020-07-29 Bristol Myers Squibb Co Substituted indole ether compounds
FI3728252T3 (fi) 2017-12-18 2023-10-18 Bristol Myers Squibb Co 4-atsaindoliyhdisteitä
BR112020012329A2 (pt) 2017-12-19 2020-11-24 Merck Patent Gmbh antagonistas de tlr7/8 e usos dos mesmos
BR112020011979A2 (pt) 2017-12-19 2020-11-17 Bristol-Myers Squibb Company compostos de indol substituídos por amida úteis como inibidores de tlr
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
AU2018390820A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
ES2904676T3 (es) 2017-12-20 2022-04-05 Bristol Myers Squibb Co Compuestos de amino indol útiles como inhibidores de TLR
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
JP2021507889A (ja) 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
AU2019268583B2 (en) 2018-05-18 2022-01-27 Novartis Ag Crystalline forms of a TLR7/TLR8 inhibitor
AU2019313441A1 (en) 2018-07-31 2021-03-18 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
KR20210080462A (ko) 2018-10-24 2021-06-30 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 이량체 화합물
WO2020227337A1 (en) 2019-05-07 2020-11-12 Bristol-Myers Squibb Company Prodrug compounds
KR20220006571A (ko) 2019-05-09 2022-01-17 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
BR112021023292A2 (pt) 2019-05-23 2022-02-08 The Univ Of Montana Composto, formulação, composição de vacina, composição farmacêutica, e, método para modular uma resposta imune em um indivíduo
JP2022550203A (ja) * 2019-10-01 2022-11-30 ブリストル－マイヤーズ スクイブ カンパニー 置換二環ヘテロアリール化合物
JP2022552159A (ja) 2019-10-04 2022-12-15 ブリストル－マイヤーズ スクイブ カンパニー 置換カルバゾール化合物
KR20220097434A (ko) 2019-11-01 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 톨 수용체 억제제로서의 치환된 피라졸 화합물
TW202200139A (zh) 2020-05-14 2022-01-01 德商馬克專利公司 用於治療冠狀病毒感染之tlr7/8拮抗劑
KR20230023717A (ko) 2020-06-11 2023-02-17 브리스톨-마이어스 스큅 컴퍼니 피부 홍반성 루푸스를 치료하기 위한 프레드니솔론 또는 히드록시클로로퀸과 조합된 tlr7 억제제
EP4168049A1 (en) 2020-06-22 2023-04-26 Bristol-Myers Squibb Company Treating rheumatoid arthritis
WO2022022489A1 (zh) 2020-07-27 2022-02-03 江苏恒瑞医药股份有限公司 吲哚稠环类衍生物、其制备方法及其在医药上的应用
CN114075212B (zh) 2020-08-14 2023-05-12 江苏恒瑞医药股份有限公司 稠合三环类衍生物、其制备方法及其在医药上的应用
CN114075219B (zh) 2020-08-14 2023-11-14 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
AR123284A1 (es) 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9
KR20230113569A (ko) 2020-11-26 2023-07-31 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 융합된 트라이사이클릭 화합물, 이의 제조 방법 및 이의 의약에서의 용도
EP4267560A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. 6-substituted indole compounds
WO2022140326A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Substituted indole compounds

Also Published As

Publication number Publication date
TW202302598A (zh) 2023-01-16
US11661431B2 (en) 2023-05-30
EP4323369A1 (en) 2024-02-21
CA3214808A1 (en) 2022-10-20
AU2022257039A1 (en) 2023-10-05
BR112023021107A2 (pt) 2023-12-12
WO2022221642A1 (en) 2022-10-20
DOP2023000219A (es) 2023-11-15
US20220389034A1 (en) 2022-12-08
KR20230171469A (ko) 2023-12-20
IL307203A (en) 2023-11-01
CR20230478A (es) 2023-11-30
US20230365594A1 (en) 2023-11-16
JP2024513945A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
CO2023013397A2 (es) Compuestos de tienopirrol
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2019000107A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014)
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
CL2020002840A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
SV2017005471A (es) Derivados de quinazolina utilizados para tratar el vih
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
MX2021004999A (es) Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos.
CL2022002695A1 (es) Inhibidores de rip1k
EA201690810A1 (ru) Мягкие пастилки, содержащие экстракт куркумы
BR112017010933A2 (pt) composição farmacêutica
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
AR095132A1 (es) Formulación en dispersión sólida de un compuesto antiviral
CL2016002400A1 (es) Formulación para higiene personal
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CL2022003812A1 (es) Inhibidores de rip1k
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
SV2018005747A (es) Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas